The combination of CD47 mAb with trastuzumab not only significantly reduced the growth of HER2+ breast tumors resistant to ADCC but also enhanced the efficacy of trastuzumab, leading to complete tumor regression (33, 34). Here, CD47 is linked to neoplasm.